Oppenheimer: We Still Love OvaScience

In a report published Wednesday, Oppenheimer analyst Rohit Vanjani discussed a recent investor meeting with

's management team, including the company's Chief Executive Officer Dr. Michelle Dipp. OvaScience noted that both patient and physician inquiries have moved higher since the company

at the Society for Reproductive Investigation (SRI) in March. The management team added that the offering clinics are using the physician posters presented at SRI as well as the case studies featuring patient experiences and results in discussions for new AUGMENT consultations. Management also stated that its patient registry data could reach the thousands, when released in early 2016. With only around 150 AUGMENT cycles in 2014 plus the 2016 registry data, even assuming a significant AUGMENT ramp in the first quarter 2016, the analyst remains confident OVAS will achieve its 2015 guidance of 1,000 cycles. The analyst further added that the company continues to guide to an AUGMENT launch in Japan in the second half of 2015 and the regulatory pathway is "relatively straightforward." Finally, Vanjani noted that shares of OvaScience fell more than 11 percent on Tuesday following a report published by the

The analyst stated that the report contains "a number of inaccuracies" and "treads over old issues." Shares remain Outperform rated with a $60 price target.